Fig. 2From: Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillanceFirst onset date of adverse drug reactions that occurred in ≥1% of patientsBack to article page